Does Male Circumcision Prevent HIV Infection? by Siegfried, Nandi
PLoS Medicine  |  www.plosmedicine.org 1071
G
iven the devastating mortality 
and morbidity associated with 
HIV/AIDS, many potential 
prevention measures against HIV 
infection have been explored. Male 
circumcision is one of these, and 
seven reviews of the literature [1–7], 
including two meta-analyses [4,5], 
have been published. However, as 
pointed out in the Cochrane systematic 
review of the subject, all studies to 
date were observational, and many 
were of poor quality. In the absence 
of any experimental evidence, no 
causal relationship between male 
circumcision and HIV prevention could 
be conﬁ  dently assumed [7]. 
The First Randomised Trial
In this issue of PLoS Medicine, Auvert 
and colleagues report results from 
the ﬁ  rst completed trial of male 
circumcision for reducing HIV 
infection in South African heterosexual 
men [8]. The authors conducted a 
randomised and blindly evaluated trial 
in a semiurban area near Johannesburg 
in which the background HIV 
prevalence rate among heterosexual 
men was 4.4%. Between July 2002 and 
February 2004, they randomised 3,274 
men, with 1,617 undergoing medical 
circumcision at the beginning of the 
trial (the intervention group) and 
1,657 remaining uncircumcised (the 
control group). The men were followed 
up at three clinic visits at 3, 12, and 21 
months, and were tested for HIV at 
each visit. 
At an interim analysis done after all 
participants had completed the 12-
month clinic visit, the Data Monitoring 
and Safety Board stopped the trial on 
the basis of the interim results. The 
results showed that, after excluding 
those men who were HIV-positive at the 
beginning of the trial (n = 146), 20 of 
the circumcised men became infected 
with HIV during the trial compared 
with 49 men in the control group. The 
risk of acquiring HIV infection was 
signiﬁ  cantly reduced by 60% in the 
men who had undergone circumcision 
(incidence rate ratio = 0.4; p < 0.001). 
All men in the control group were then 
offered circumcision. 
Strengths of the Study
One strength of this study is that 
participants were drawn from the 
general population, increasing the 
generalisability of the ﬁ  ndings. In 
addition, the relatively low loss to 
follow-up (7.9% overall) demonstrates 
that trials of this nature can be 
adequately conducted in poorly 
resourced settings. 
The researchers, the participants, 
and their supporters should be 
congratulated for attempting and 
successfully completing a trial as 
complex as this. The interim analysis 
was planned, and used an appropriate 
statistical stopping rule, thus reducing 
the chance of randomly exaggerated 
treatment effects [9].
Concerns about the Randomisation
The researchers did not report how 
the randomisation sequence was 
generated, and they used an unusual 
form of allocation to comparison 
groups. As participants requested to 
be actively involved in the allocation 
process, they were invited to choose 
an envelope from a pre-prepared 
box of ten envelopes. After each 
allocation, this box was then reﬁ  lled 
with envelopes from another box 
containing ﬁ  ve envelopes for the 
intervention group and ﬁ  ve for the 
control group. Although the envelopes 
were equally distributed in the second 
box, this was not necessarily the case 
with the participant box. This unequal 
distribution partly explains why the 
numbers in the comparison groups 
differ by a total of 40. 
Perhaps of more concern is that 
allocation concealment may have 
been inadequate given that the 
centre manager was responsible for 
ﬁ  lling both boxes of envelopes, and 
potentially could have subverted the 
treatment allocation, thus introducing 
selection bias. Inadequate allocation 
concealment has been shown to be 
associated with exaggerated treatment 
effects [10,11]. Despite this, as the 
baseline characteristics of both 
comparison groups are similar and 
the sensitivity analyses of the results 
are robust, the effect of these quality 
parameters is probably negligible. 
Ethical Concerns
Although it is unlikely to have affected 
the results, the trialists decided not 
to inform participants of their HIV 
status, neither at the beginning or 
end nor during the trial. The authors 
argue that at the time of the trial, 
antiretrovirals were unavailable in the 
public health sector in South Africa, and 
that the participants received intensive 
counselling on how to avoid contracting 
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and transmitting HIV. The researchers 
chose not to inform those who were 
HIV-positive at the beginning because 
they were concerned that exclusion 
from the trial would be stigmatising. 
Men were encouraged to attend 
voluntary counselling and testing (VCT) 
in a nearby public clinic or in a special 
VCT centre in the same building as the 
investigation centre. Men who tested 
positive for other sexually transmitted 
infections that were treatable locally 
were referred to the local clinic. 
Avoiding stigmatisation is an 
important consideration, but it could 
be argued that if withholding HIV 
status was the only feasible option, then 
the conditions were not suitable to 
conduct such a trial. In fact, referring 
participants to the local VCT centre 
or the clinic for treatment of other 
sexually transmitted infections may 
have resulted in more stigmatisation, 
as this referral would have been visible 
to others rather than only to those 
within the trial processes. Some might 
argue that the nondisclosure of HIV 
status fails the test of beneﬁ  cence (the 
obligation to prevent and remove 
harms and to promote the good of 
a person by minimising the risks 
incurred to the research participant 
and maximising the beneﬁ  ts to them 
and others). Not only were participants 
affected by nondisclosure, but so were 
their partners. It is unlikely that this 
approach would be tolerated in a more 
developed setting [12]. 
Policy Implications
The trialists suggest that circumcision 
could be rapidly incorporated into 
national plans of countries where 
circumcision is not widely practised, 
while recognising that promotion 
of circumcision may also lead to 
undesirable outcomes such as 
undermining condom promotion. 
They are right to argue that we need 
to seriously consider circumcision as 
a potential prevention method, but 
it seems wise to be more cautious 
in making recommendations 
for policy. Within- and between-
country differences in culture, 
religion, and social norms will need 
to be very carefully considered 
before implementing circumcision 
programmes. Crucially, the results 
of two additional trials underway 
in Uganda and Kenya are awaited. 
Considering the results of all three trials 
together is likely to provide us with 
stronger evidence to guide policy.  
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